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Abstract
Rationale The basal ganglia play an important role in
motor control, which is dependent on dopaminergic input.
Preparation of a motor response has been associated with
dopamine release in the basal ganglia, and response
readiness may therefore serve as a pharmacodynamic
marker of dopamine activity.
Methods Wemeasured response readiness using the amplitude
of the contingent negative variation (CNV), a slow negative
shift in the electroencephalogram. The CNV is evoked in a
paradigm in which a warning stimulus (S1) signals the
occurrence of the imperative stimulus (S2) 4 s later, to which
the participant has to respond. CNV was assessed in healthy
volunteers after administration of placebo or 10, 20 or 40 mg of
methylphenidate, a catecholamine re-uptake blocker which
primarily enhances the synaptic concentration of dopamine and
to a lesser extent also noradrenaline. In addition, participants
filled out two visual analogue scales measuring subjective
ratings of mood and alertness: Profile of Mood States and Bond
and Lader.
Results Methylphenidate dose dependently increased CNV
amplitude and decreased reaction times. Furthermore,
participants reported improved mood, feeling more alert,
vigorous and content and less angry and tired after
methylphenidate.
Conclusions These results indicate that dopamine availability
increases response readiness as measured by the CNV
paradigm. The CNVappears to be a good candidate biomarker
for assessing changes in dopaminergic function by treatments
that either directly or indirectly target the dopaminergic
system.
Keywords Contingent negative variation .
Methylphenidate . Event-related potentials . Response
preparation . Dopamine
Introduction
Dopamine abnormalities are implicated in neuropsychiatric
diseases such as Parkinson’s disease, schizophrenia and
attention deficit hyperactivity disorder (ADHD; Iversen and
Iversen 2007; Nieoullon 2002), but the precise nature of
these disturbances and their treatments remains to be
understood. This drives the relevance of dopamine-related
research and the value of new tools aiding this research. In
the present study, a candidate biomarker of dopamine
activity is proposed and validated.
The contingent negative variation (CNV) is a slow negative
shift in the EEG that can be observed between a warning signal
and an imperative stimulus during a reaction time task. The
occurrence of this wave has been associated with expectation,
anticipation, orientation, attention, intention to act, motivation
and response readiness (Bares et al. 2003; Tecce 1972; van
Boxtel and Brunia 1994; Walter et al. 1964).
Evidence from studies with Parkinson’s disease patients
using intracranial electrodes and studies combining EEG/
fMRI techniques suggests that the CNV is generated in the
basal ganglia (Bares and Rektor 2001; Fan et al. 2007;
Nagai et al. 2007; Oishi et al. 1995; Rektor et al. 2003,
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2004). An important neuromodulator within the basal
ganglia is dopamine which, consequently, has been considered
a possible biochemical mechanism underlying the CNV
(Amabile et al. 1986). Converging evidence suggests that
CNV may indeed be modulated by dopamine availability
(Amabile et al. 1986; Kopell et al. 1974; Oishi et al. 1995;
Tecce 1991; Tecce and Cole 1974; Tecce et al. 1975).
Consequently, changes in CNV may signal alterations of
dopamine levels in the brain, and the CNV may thus be a
basal ganglia originated marker of dopamine activity.
Research with agents affecting other neurotransmitters
such as serotonin, noradrenaline and acetylcholine showed
that the influence on the CNV is indirect (through interactions
with the dopamine system), absent or dose dependent (Ashton
et al. 1976, 1980; Ashton and Rawlins 1978; Hansenne et al.
2000; Mulder et al. 2002). Benzodiazepines decrease CNV
amplitude (Ashton et al. 1976; Papart et al. 1997; Rockstroh
et al. 1991).
An early and a late CNV component or ‘wave’ can be
distinguished (Klorman and Bentsen 1975). The early wave
is thought of as an orientation response (Klorman and
Bentsen 1975) whereas the late CNV consists of a readiness
potential and stimulus preceding negativity (Brunia 1988;
van Boxtel and Brunia 1994). The late CNV reflects motor
preparation and stimulus anticipation (Brunia and van
Boxtel 2001) and is the wave targeted here. To observe
both waves, an interval of 4 s is used in the current study.
Before the CNV can be successfully applied as a
dopaminergic biomarker, its sensitivity needs to be estab-
lished. It is essential to know both the minimal change in
dopamine levels that can be detected by means of the
CNV and the dose–response curve of the paradigm.
Therefore, this study measured CNV amplitude across a
range of doses of a dopamine-enhancing drug. The drug
chosen was methylphenidate. Methylphenidate inhibits
dopamine re-uptake by blocking the dopamine transporter
(DAT) and thus enhances dopamine availability (Volkow
et al. 1998a), has a wide safe dose range, is generally well
tolerated and has been used for similar purposes in
previous studies (Volkow et al. 1998b, 2008). Methylphenidate
is used to treat ADHD and narcolepsy. The maximum dose in
children with ADHD is 60 mg/day. PET research has
shown that methylphenidate leads to dose-dependent
DAT blockade with a dose of 5 mg producing a 12%
blockade, 10 mg 40%, 20 mg 54%, 40 mg 72% and
60 mg 74% (Volkow et al. 1998a). Hence, therapeutic
doses of methylphenidate are likely to block more than
50% of DAT. Tmax is observed 1–3 h after intake, with a
half life of approximately 3 h (Leonard et al. 2004;
Spencer et al. 2006).
Participants were treated with 10, 20 and 40 mg of
methylphenidate, and in addition to CNV amplitude, task
performance and subjective drug effects were also measured.
It was expected that CNV amplitude would show a dose-
related increase and that reaction time would dose
dependently decrease. Based on the PET research cited
above and other previous studies with methylphenidate
(Cooper et al. 2005; Hermens et al. 2007), it was expected
that a dose of 10 mg would lead to minimal effects. The
largest effects were expected with 40 mg of methylphenidate,
whereas 20 mg was expected to induce intermediate effects.
Materials and methods
Participants
Nineteen healthy male volunteers (mean age=23.4, SD=5.4,
range=19–37) were selected and paid to participate.
Participants were recruited by means of advertisement posters
in university buildings and advertisements in the university
newspaper. Prescreening occurred using a medical history
questionnaire and was followed by medical examination.
The main inclusion criteria were between 18 and 40 years
of age, body mass index between 18 and 30 kg/m2 and
right-handed. The main exclusion criteria were history or
presence of mental or physical disorders as assessed by
medical history and anamnesis at inclusion, reported
presence of psychiatric diseases in first degree relatives,
previous drug dependence, self-reported regular drug use,
smoking more than five cigarettes per day and consumption
of more than 21 alcohol units per week or more than five
caffeine containing drinks per day (average reported daily
use <2). In addition, volunteers with polymorphisms of the
CES1 gene indicative of being a poor metaboliser of
methylphenidate were excluded. One participant was
excluded based on this criterion.
All subjects gave written informed consent. The study
was carried out in accordance with the declaration of
Helsinki and approved by the medical ethical committee of
Maastricht University.
Design
The study was conducted according to a double-blind,
placebo-controlled, four-way crossover design. Between the
testing days, a period of at least 48 h elapsed, but generally
testing days were scheduled approximately 1 week apart.
Each participant received one of four single treatments
including placebo (PLA) and 10, 20 and 40 mg methyl-
phenidate (M10, M20 and M40) on each testing day. The
order of the treatments was randomized following a
Williams Latin square design resulting in four different
sequences constructed using SAS programme.
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Dependent measures
EEG measurement
During two response preparation tasks, EEG was measured
using 11 electrodes placed on the scalp, according to the
10–20 system at the Fz, F3, F4, Cz, C3, C4, Pz, P3, P4, O1
and O2 electrode positions. The remaining electrodes
consisted of four to register vertical and horizontal eye
movements, two on the mastoids for reference and one on the
forehead as ground. Data were recorded with a 1,000-Hz
sample rate and filtered online between 0.05 and 100 Hz.
Offline, data were first screened for artefacts and a low pass
filter of 10 Hz was applied on all data. Next, epochs were
extracted from the continuous EEG. Each epoch lasted
5,100 ms, starting 100 ms before S1 and ending 1,000 ms
after S2. A baseline correction was applied to the whole
epoch, using the 100 ms interval preceding S1 as reference.
Averaging the sequential epochs yielded a S1 stimulus locked
event-related potential (ERP). CNVamplitude was calculated
by averaging the amplitude over the last 100 ms before S2.
Since the CNVamplitude was expected to be maximal at the
central electrodes (Brunia 1988; Klorman and Bentsen 1975;
van Boxtel and Brunia 1994), Cz, C3 and C4 were of main
interest and are reported in the Results section.
Response preparation tasks
CNV stoplight task In the CNV stoplight task, participants
watched the computer screen and were presented with a
filled red circle (S1) on a black background. After 4 s, the
red circle turned green (S2). Subjects were instructed to
respond to the green circle by pressing a button on a table
mounted response box as fast as they could. Each test
consisted of 32 trials. Reaction time to the onset of S2 was
measured in each trial and averaged over the test.
CNV lines task A CNV task with a long preparation time
can be boring, and participants may become less motivated
to produce speeded responses to the imperative stimulus.
This may have a detrimental effect on CNV amplitude.
Therefore, a new task involving dynamic stimuli was
designed. In the CNV lines task, S1 was the appearance
of two red line drawings at the bottom left- and right-hand
corner. The lines were oriented at a 90° angle to each other
and after appearing both moved towards the centre of the
screen. After 4 s, the lines crossed and turned green (S2).
At this moment, participants pressed a response button as
fast as possible. In two thirds of the trials, a horizontal
yellow bar partially blocked the view of the lines as they
moved towards the centre of the screen, but the lines were
always visible at the moment of crossing. The yellow bar
could be small or large, blocking less or more of the
trajectory of the lines as they moved towards the centre.
The trials with the small bar are collectively called ‘lines 1’,
those with the large bar ‘lines 2’ and those without a bar
‘lines 3’. Of each type, 25 trials were presented. Reaction
time was measured and averaged per trial type. These three
variations of the new paradigm and the standard paradigm
were compared in order to find out which task led to
optimal CNV amplitude.
Subjective measures
Participants completed two rating scales of subjective
effects, the Profile of Mood States (POMS; McNair et al.
1992) and the Bond and Lader (B&L) visual analogue
scales (Bond and Lader 1974). These rating scales involved
the presentation of 16 (B&L) or 32 (POMS) bipolar items
presented at the ends of a horizontal line on a computer
touch screen. Each item consisted of two words describing
mood states. Participants had to score their preference for
either of the items in accordance with their mood by
marking the line closer to one of the two words. Dependent
measures were factor scores on the dimensions Alertness,
Contentedness and Calmness (B&L) and Depression,
Anger, Fatigue, Vigour and Tension (POMS).
Blood plasma values and physiological measures
Blood samples were drawn in order to measure blood levels
of the drug and neuroendocrine responses. Dependent
variables were changes in levels of methylphenidate,
prolactin and cortisol in blood during the testing days.
Physiological measures including systolic and diastolic
blood pressure and heart rate were also taken.
Procedure
A training session in which all behavioural tasks were
practiced took place within 2 weeks before the first testing
day. Participants abstained from alcohol during the last 24 h
prior to each testing day and from caffeine containing
drinks during the testing days. On testing days, they were
collected at their home and arrived at the lab in fasted
condition at either 8.00 am or 8:30 am. Inclusion exclusion
criteria were checked, including a drug screen (which tested
presence of the following substances in urine: cannabis,
opiates, cocaine, methamphetamine, benzodiazepines,
amphetamines) and blood alcohol concentration measurement.
Next, EEG electrodes and a catheter were placed, and
participants were given a standardized meal for breakfast at
80 min per dose (t=−80). At t=0, participants ingested four
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identically appearing capsules with water that all contained
either PLA, M10, M20 or M40. Participants went through
seven cycles of testing at t=−60, 30, 60, 120, 180, 240 and
300 min relative to dosing. At t=220, a standard light lunch
was served. Each cycle included a fixed order of the CNV
stoplight task, the CNV lines task, POMS, B&L, registration
of heart rate and blood pressure and the drawing of blood
samples. After collection of the blood samples, the catheter
was cleaned with heparin dissolved in isotonic saline, and
blood samples were centrifuged for 10 min at 4,000 rpm.
Plasma was stored at −20°C and frozen PK samples were
moved to a −80°C freezer. After the last measurement, the
EEG electrodes and catheter were removed and participants
were transported home by taxi.
Data analysis
Data were analysed using repeated measures analysis of
covariance analysis. In this mixed model, the repeated
measures of drug (independent variable) on the dependent
variables (mean CNV amplitude, reaction time, scores on
POMS and Bond & Lader, heart rate, blood pressure,
cortisol and prolactin levels in blood, Tmax and Cmax) were
tested using baseline (measurement of the dependent
variable at t−60) as a covariate and period (first, second,
third or fourth testing day) as between subjects variable.
Since treatment consisted of different doses of the same
drug and the lower doses may have no or little effect on
amplitude, response time and subjective measures, the
likelihood of finding a main effect on these measures may
be rather small, even though higher doses may have a
significant effect. Therefore, main effects of drug were not
evaluated for the amplitude and reaction time data and the
subjective measures. Instead, a priori planned comparisons
between each dose relative to placebo were tested for
significance, at p<0.05, using LSD correction. This is not
the case for blood plasma values and physiological
measures, where even small doses of the drug were
expected to exert significant effects on heart rate, blood
pressure, cortisol and prolactin levels and Tmax and Cmax.
Therefore, main effects are reported for these measures at a
significance level of p<0.05. Post hoc testing using LSD
correction was done to find out which doses had an effect.
Results
CNV amplitude
Averaged CNV waves recorded during performance of
response preparation tasks are shown in Fig. 1. Mean
differences on CNV amplitude relative to morning baseline
are depicted in Fig. 2 for stoplight and lines 2 at Cz. Mean
differences on CNV amplitude relative to morning baseline
and results of significant difference testing are presented in
Table 1.
Increases in CNVamplitude after methylphenidate measured
at t60 and t240 account for, respectively, 27% and 46% of the
total amount of significant differences observed in all
paradigms and at all electrodes. More specifically, the effects
at 1 and 4 h post-dosing were as follows (for a complete
overview, see Table 1): Significant increases in CNVamplitude
after methylphenidate during performance of the stoplight task
were observed at t60 after intake of 40 mg of the drug at Cz,
C3 and C4 (Cz: p<0.013, C3: p<0.035, C4: p<0.049). At t60,
the amplitude was also larger after M10 at Cz (p<0.045). At
t240, M40 lead to a significantly increased amplitude at all
three electrodes (Cz: p<0.032, C3: p<0.028, C4: p<0.017).
During performance of the lines task version 1, amplitude
was significantly larger after 40 mg of methylphenidate
compared to placebo at t240 at the Cz electrode (p<0.025).
Analysis of the lines task version 2 showed significantly
higher amplitudes after M40 at t60 at the C3 electrode
position (p<0.035) and at t240 at C4 (p<0.014). At Cz, all
doses led to higher CNV amplitude at t240 (M10: p<0.025,
M20: p<0.014, M40: p<0.006).
Fig. 1 Grand average ERPs showing a clear CNV wave during the
stoplight (a) and lines 2 (b) response preparation tasks. The ERPs
depicted were recorded at Cz, at t240 relative to dosing
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Reaction time data
Mean differences on reaction times relative to morning
baseline are depicted in Fig. 2 for stoplight and lines 2.
Mean differences on reaction time relative to morning
baseline and results of significant difference testing are
presented in Table 2.
Reaction times to the imperative stimulus in the stoplight
task were shorter after 40 mg of methylphenidate compared
to placebo at all time points. At t240, reaction times were
also shorter after 10 and 20 mg of methylphenidate.
On the lines task, version 1, reaction times were also
shorter after 40 mg of methylphenidate at t60, t120, t240
and t300. On version 2 of the lines task, reaction times were
shorter after 40 mg from t60 to t300 and after all doses at
t120. Reaction times were also shorter after the two lower
doses at t120 and t240. Finally, M40 decreased reaction
times on the lines 3 task on all time points. In addition,
reaction times were shorter after 10 mg of methylphenidate
at t120 and t240.
Subjective measures
The Bond & Lader factor scores indicated that participants
felt more alert between 1 and 2 h after 20 and 40 mg drug
intake and more content from 1 to 3 h after 20 mg of
methylphenidate. Furthermore, analysis showed increased
scores for calmness after 40 mg of methylphenidate at t120
but decreased scores after 10 mg at t180 and t300.
Analysis of POMS factor scores indicated that after
methylphenidate, participants experienced improved mood
(all doses) and less anger (20 mg) compared to placebo
between 1 and 3 h after drug intake. Factor scores indicated
less fatigue at t60, t120 and t240 after 20 and 40 mg of
methylphenidate, more vigour from 1 to 4 h after
methylphenidate intake (all doses) and less tension after
40 mg of methylphenidate at t30 and t300.
Blood plasma values
Mean levels of cortisol and prolactin in blood and results of
significant difference testing are presented in Table 3.
Methylphenidate significantly increased cortisol levels. At
t60, cortisol levels were significantly higher after all doses of
methylphenidate when compared to placebo (F3,41.43=9.207,
p<0.001). At t120 (F3,40.71=11.964, p<0.001), t180 (F3,
41.86=8.238, p<0.001) and t300 (F3,39.02=8.663, p<0.001)
cortisol levels were significantly higher after M20 and M40
but not M10. At t240, there was no effect of drug on cortisol
levels (F3,39.24=0.647, p>0.05).
Fig. 2 Mean difference CNV
amplitudes and reaction times
relative to morning baseline at
t30, 60, 120, 180, 240 and
300 min relative to dosing in the
stoplight (amplitudes at Cz, a;
reaction times, c) and lines 2
(amplitudes at Cz, b; reaction
times, d) response preparation
tasks. Error bars are only shown
for PLA (placebo) and M40
(methylphenidate, 40 mg)
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Prolactin levels were lower after all doses of methyl-
phenidate in comparison to placebo from t60 to t180 (t60:
F3,36.32=13.247, p<0.001; t120: F3,38.18=32.293, p<0.001,
t180: F3,39.97=29.558, p<0.001) and after M20 and M40 at
t240 (F3,37.11=4.702, p<0.01) At t300, the effect was no
longer significant (F3,37.52=0.945, p>0.05).
Maximum methylphenidate concentration in blood differed
significantly between treatment conditions (Cmax: M10 mean
(SEM)=4.9 (0.4); M20 mean (SEM)=9.3 (0.7); M40 mean
(SEM)=17.2 (1.2), F2,30=140.130, p<0.001). Tmax was equal
for all treatments (mean (SEM)=2.9 (0.2), F2,30=0.134,
p>0.05).
Physiological measures
Absolute baseline values of physiological measures and mean
differences relative tomorning baseline and results of significant
difference testing are presented in Table 3. Methylphenidate (20
and 40 mg) significantly increased heart rate compared to
placebo from 1 up to 5 h after drug administration (t60: F3,
43.88=10.194, p<0.001; t120: F3,44.04=14.395, p<0.001; t180:
F3,42.78=13.325, p<0.001; t240: F3,38.97=9.195, p<0.001;
t300: F3,41.84=7.271, p<0.001). At t120 and t180, all doses
significantly increased heart rate. Systolic blood pressure was
significantly higher after M20 and M40 compared to placebo
at t60 (F3,40.13=5.433, p<0.01) and after all doses at t120
(F3,40.46=5.178, p<0.01). At t180, t240 and t300, there was no
main effect of drug on systolic blood pressure, but systolic
blood pressure was higher compared to placebo after M10
(t180: p<0.05; t240: p<0.05; t300: p<0.05) and M20 (t180:
p<0.05; t240: p<0.05) as was revealed by the planned
contrasts. Diastolic blood pressure significantly increased 1 h
after intake of 20 and 40 mg of methylphenidate compared to
placebo (t60: F3,42.39=5.279, p<0.01). This effect remained
significant until 4 h after drug intake (t120: F3,43.39=4.808,
p<0.01; t180: F3,43.73=4.468, p<0.01; t240: F3,42.04=3.796,
p<0.05).
Discussion
In the current study, the effects of different doses of
methylphenidate on the late CNV wave were assessed in
order to explore the utility of the CNV amplitude as a
marker of dopamine activity. In line with the expectations,
methylphenidate dose dependently increased CNV ampli-
Stoplight Lines 1 Lines 2 Lines 3
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM)
t30 PLA 11.4 (4.4) 5.4 (4.4) 1.5 (3.5) −0.1 (4.3)
M10 7.0 (6.3) 4.0 (3.3) 0.4 (4.6) −5.5 (2.6)
M20 7.3 (4.9) 6.2 (4.0) −1.0 (3.1) 1.2 (4.1)
M40 −3.1** (3.8) −3.6 (5.6) −10.3 (6.3) −12.6** (5.4)
t60 PLA 20.7 (5.4) 5.9 (4.6) 1.4 (3.8) 2.4 (4.2)
M10 9.4 (7.1) 5.7 (3.7) 6.6 (6.0) 0.7 (5.4)
M20 8.5 (6.0) 1.7 (3.7) −3.5 (4.8) −6.3 (4.4)
M40 −8.7*** (5.4) −9.4** (5.9) −16.5** (6.9) −14.8** (6.5)
t120 PLA 11.4 (4.5) 6.0 (4.6) 1.3 (3.0) −3.7 (4.5)
M10 −3.1 (6.4) −2.0 (2.7) −7.2** (3.5) −11.7*** (2.7)
M20 2.5 (4.4) −4.4 (3.1) −14.5** (3.4) −11.9 (3.9)
M40 −11.6*** (6.8) −9.5** (5.5) −15.0** (6.8) −20.2*** (6.0)
t180 PLA 12.6 (5.7) 0.6 (4.6) −4.7 (3.9) −6.3 (5.2)
M10 −0.4 (9.3) 1.2 (2.9) −5.1 (4.2) −8.7 (3.0)
M20 1.5 (5.9) −1.5 (2.7) −8.0 (3.2) −10.2 (5.2)
M40 −11.9** (6.1) −11.2* (5.8) −20.5** (6.7) −22.0*** (6.2)
t240 PLA 20.7 (4.3) 3.5 (3.8) 5.4 (5.4) −4.3 (5.2)
M10 −2.3** (9.1) −3.0 (2.7) −6.7*** (4.1) −11.6** (2.2)
M20 2.0** (3.9) −1.6 (4.9) −14.6*** (3.8) −10.8 (5.1)
M40 −15.9**** (8.6) −10.2** (5.7) −18.9**** (5.7) −19.1*** (5.8)
t300 PLA 16.7 (7.8) 4.4 (4.5) −0.4 (5.6) −5.8 (5.4)
M10 12.4 (8.1) 2.2 (3.4) −5.6 (4.7) −8.5 (2.6)
M20 1.2* (5.0) −2.9 (3.1) −11.3 (3.5) −14.2 (4.9)
M40 −5.3** (8.0) −7.0*** (4.7) −14.6** (5.2) −16.8** (5.8)
Table 2 Mean differences
(SEM) on reaction times relative
to morning baseline for
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tude and decreased reaction time in both response prepara-
tion paradigms. Furthermore, subjective measures indicated
that participants experienced improved mood, felt more
alert and vigorous and less angry and tired after methyl-
phenidate. Physiological measures including blood pressure
and heart rate increased, confirming previous findings
(Volkow et al. 1996). These results indicate that dopamine
activity increases response readiness as measured by the
CNV paradigm.
CNV has been previously reported to be sensitive to
dopaminergic modulation (Amabile et al. 1986; Kopell et
al. 1974; Oishi et al. 1995; Tecce 1991; Tecce and Cole
1974; Tecce et al. 1975). However, little was known about
dose-related effects. In the present study, the effects on
reaction time and CNV amplitude could be detected after a
dose of methylphenidate as low as 10 mg, demonstrating the
sensitivity of the CNV paradigm to changes in dopamine
availability. In support of a dose–response relationship, the
effects were most prominently and consistently observed after
the highest dose of methylphenidate. Importantly, the current
effects are measured on the late CNV wave. Previous studies,
using shorter intervals between S1 and S2 (Luthringer et al.
1999), may possibly have measured a composite of the early
and late wave. An internal validation of the paradigms used
in this study is provided by correlation analysis, which
revealed consistent correlations between the difference
scores for response time and CNV amplitude at Cz in the
40 mg of methylphenidate condition in all paradigms at
all time points, ranging between 0.46 and 0.96 with
average of 0.78. This correlation also emerged for the
Table 3 Means (SEM) of cortisol and prolactin levels in blood, absolute baseline values and mean differences (SEM) relative to morning baseline
for heart rate, systolic and diastolic BP at all time points
Cortisol Prolactin Heart Rate BP systolic BP diastolic
Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM)
BL PLA 491 (27) 11.4 (0.9) 66.3 (2.2) 133.9 (3.3) 73.8 (3.8)
M10 504 (28) 11.6 (1.2) 66.7 (2.7) 130.6 (2.5) 71.8 (2.8)
M20 576 (27) 13.6 (1.3) 67.7 (2.3) 133.1 (3.0) 70.7 (1.7)
M40 512 (43) 11.8 (1.2) 66.3 (2.5) 133.2 (2.7) 72.7 (1.7)
t30 PLA −2.1 (1.4) −0.2 (1.8) −0.5 (1.6)
M10 −3.1 (1.4) −1.0 (2.1) −0.8 (3.0)
M20 −2.5 (1.1) −1.8 (2.0) 0.8 (1.3)
M40 −2.9 (0.9) −1.8 (2.0) 1.1 (1.7)
t60 PLA 325 (21) 9.0 (0.6) −6.8 (1.2) −6.8 (2.7) −2.7 (3.2)
M10 405* (35) 7.6** (1.0) −3.6 (2.0) −1.5 (1.6) 2.2 (3.9)
M20 454** (31) 7.0*** (0.6) −0.5** (1.4) 0.9** (2.3) 6.4** (1.5)
M40 510*** (32) 6.4*** (0.9) 2.9*** (2.1) 2.9*** (2.4) 5.7** (2.3)
t120 PLA 300 (18) 8.5 (0.7) −9.6 (1.1) −5.5 (1.8) −0.6 (2.9)
M10 332 (30) 6.4*** (0.9) −5.8* (1.4) 2.3* (2.4) 2.2 (3.3)
M20 409** (31) 5.8*** (0.7) −2.4*** (1.4) 0.8* (2.6) 6.6* (1.7)
M40 481*** (35) 4.4*** (0.4) 0.9*** (2.2) 3.7*** (2.3) 5.6** (2.2)
t180 PLA 313 (21) 7.9 (0.7) −9.8 (1.1) −4.6 (2.3) −1.7 (3.8)
M10 347 (25) 6.4*** (0.8) −5.5* (1.6) 2.0* (1.5) 0.4 (3.3)
M20 411** (28) 5.8*** (0.7) −2.6*** (1.6) 0.7* (2.1) 6.1** (1.9)
M40 411*** (30) 4.9*** (0.7) 1.3*** (1.8) −0.2 (2.5) 3.3* (1.6)
t240 PLA 400 (31) 10.1 (1.1) 0.2 (1.6) −0.4 (2.5) −5.0 (3.0)
M10 419 (24) 9.1 (0.8) 1.3 (1.6) 5.0* (2.1) −0.1 (3.9)
M20 423 (28) 8.0** (0.8) 4.9** (2.0) 5.3* (2.0) 2.9* (1.5)
M40 457 (24) 6.8** (0.8) 7.9*** (1.8) 2.9 (1.9) 2.5** (1.6)
t300 PLA 281 (16) 9.8 (0.8) 1.0 (1.6) −3.0 (2.4) −3.1 (3.0)
M10 312 (21) 9.3 (1.0) 0.5 (1.6) 3.7* (1.8) 0.3 (3.2)
M20 354** (18) 9.6 (1.0) 4.4* (1.3) 1.2 (2.3) 2.2 (1.3)
M40 369*** (19) 8.0 (0.7) 6.6** (1.6) −1.9 (2.2) 0.4 (1.9)
BP blood pressure
*p<0.05; **p<0.01; ***p<0.001 (significant effects)
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lower doses but a little less consistent, which is again
indicative of a dose–response relationship. The lower
doses may generate more variance which may less often
lead to significant correlations.
Because methylphenidate inhibits re-uptake of dopamine,
but also of noradrenaline (Arnsten and Dudley 2005), it
cannot be stated with absolute certainty whether the current
findings should be ascribed solely to increased dopamine
levels. Dopamine levels in the brain cannot be measured
directly, but changes in prolactin level in blood are a good
surrogate marker since the prolactin level is known to rise as
the dopamine level decreases and vice versa (Ben-Jonathan
1985). The decrease in prolactin levels observed here
suggests that methylphenidate did successfully increase
central dopamine levels.
Methylphenidate not only enhanced CNV amplitude but
also increased response speed. As Fan et al. (2007)
suggested, it seems that anticipation of the response, as
reflected by CNVamplitude, improves response preparation
and execution. Between S1 and S2, two waves can be
observed, the early and the late CNV wave (Klorman and
Bentsen 1975). In this study, the late CNV wave was
investigated. The late wave is thought to be a mixture of a
readiness potential and stimulus preceding negativity
(Brunia and van Boxtel 2001). Improved performance
may be the result of better motor preparation, increased
anticipatory attention or a combination of both.
Based on the literature, it was expected that methylphenidate
levels in the blood would peak 2 h after drug intake
(Spencer et al. 2006; Volkow et al. 2002). In the current
study, Tmax was observed somewhat later, almost 3 h after
intake. Although methylphenidate reaches a plateau between
2 and 3 h, a delay in reaching Tmax may possibly be related to
the composition of the breakfast (Patrick et al. 2007).
Behavioural effects already appeared at 30 min after drug
intake and were still present after 5 h. The effects on the
EEG measures were more dispersed in time. Moreover,
the effects clustered mainly around two time points, at
approximately 1 and 4 h after drug intake. In other words, the
effects are observed relatively shortly after drug intake and 1 h
after Tmax.
The current method does not allow source localization.
However, previous research suggests that the CNV is
generated in the basal ganglia (Fan et al. 2007; Nagai et al.
2004). Taking into account the neuroanatomic projections of
the dopaminergic pathways, the effect observed 1 h after
drug intake may be mediated by a fast response of the
nigrostriatal pathway, being responsible for an early attention
enhancing effect. This idea is supported by our observation
that participants felt more alert this time point. The late
effect, on the other hand, is more likely to be mediated by
the mesocortical pathway, which may be responsible for
the top-down control of anticipatory processes affecting
response readiness (Brunia and van Boxtel 2001; Fan et al.
2007). Alternatively, the schedule at testing days may have
played a role in the timing of the effects. Whereas
participants were probably rather energetic at t60 and t240,
before which they just had a lunch break, they may have
been less focused at t120 and t180. However, this only partly
fits with the subjective effects reported by the participants.
The pattern of effects was quite similar for behavioural and
EEG data. Both measures were modulated the most in the
stoplight and lines 2 version of the task. There were only
subtle differences between these tasks with respect to the
methylphenidate effect on both response time and amplitude.
However, since the lines 2 version is a little more attractive to
participants, this task may be preferred for future use.
Generalization of the results may be limited by the fact
that only male participants were included. Furthermore,
taking into account the number of tasks administered, the
testing days may have been rather demanding for the
participants. This may have caused detrimental effects on
performance or decrease of motivation. A limitation of the
Bond and Lader visual analogue scale is that the calmness
scale is based on very few (two) items. Therefore,
interpretation of this scale warrants caution.
In conclusion, the current findings indicate that methyl-
phenidate dose dependently increases response readiness.
In sum, the CNV appears to be a good candidate biomarker
for assessing changes in the dopaminergic function by
treatments that either directly or indirectly target the
dopamine system. Future research should aim to dissect
the pharmacological selectivity of the CNV.
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